MitoQ vs CoQ10

The Importance of Mitochondria-Targeted Antioxidants

Coenzyme Q10 (CoQ10) and mitoquinol (MitoQ) share the same redox-active quinone head, but they are built to solve different problems. CoQ10 is an endogenous electron carrier and membrane antioxidant, and oral supplementation aims to replete stores that can fall with age, statin use and certain genetic defects.¹,² Its large, highly lipophilic structure limits intestinal absorption and gives it no specific route into mitochondria.¹  

Mitoquinol attaches a shortened quinone to a lipophilic triphenylphosphonium cation, which uses the mitochondrial membrane potential to concentrate the molecule at the inner mitochondrial membrane, where much of the cell’s reactive oxygen species are produced.⁴,¹⁷ The molecules are therefore not interchangeable: CoQ10 can restore electron transport in deficiency, whereas mitoquinol is a targeted, recyclable antioxidant that does not substitute for CoQ10 in the respiratory chain.⁵,⁶ Head-to-head human data remain limited to a single six-week trial.⁸ 

Is MitoQ Just a Better CoQ10? 

For many practitioners, CoQ10 is the default mitochondrial supplement. It has decades of clinical use, a reassuring safety record and a landmark outcome trial in chronic heart failure.³ So when patients ask whether mitoquinol is simply “a better CoQ10,” the more useful question is what each molecule is designed to do once it is swallowed. A supplement can only act where it arrives. CoQ10 has to cross the gut wall, travel in lipoproteins, enter cells and then reach the inner mitochondrial membrane, and each step loses a share of the dose.¹ Mitoquinol was engineered specifically to shortcut the final, hardest step.⁴ 

This means that these two molecules answer different problems. A patient with depleted CoQ10 needs the electron carrier itself replaced. A patient whose mitochondria are intact but under sustained oxidative pressure (as in vascular ageing or high training loads) may benefit more from an antioxidant directed at the source of that pressure.¹⁰,¹¹ Understanding the delivery problem is what lets a practitioner choose, combine or sequence these antioxidants. 

Why CoQ10 Struggles to Reach the Mitochondria 

The Problem with Delivering CoQ10 to the Inner Mitochondrial Membrane 

Mitochondria generate ATP by passing electrons along the electron transport chain (ETC) in the inner mitochondrial membrane. CoQ10 sits at the centre of that process. It collects electrons from complexes I and II and carries them to complex III.¹ In its reduced form, ubiquinol, it also protects membrane lipids from peroxidation and helps regenerate vitamin E.¹ 

The same electron flow is an unavoidable source of reactive oxygen species (ROS). Small amounts act as signals; larger or sustained amounts damage cardiolipin, membrane lipids, proteins and mitochondrial DNA.¹⁷ The antioxidant defense therefore needs to work inside the inner membrane, not merely in plasma. 

This is where oral CoQ10 meets its limits. It is one of the most hydrophobic molecules in the body, with a 50-carbon isoprenoid tail. Absorption depends on bile, dietary fat and formulation, and is low and saturable at higher single doses.¹ Once absorbed, CoQ10 travels in lipoproteins and enters tissues slowly. No dedicated transporter carries it into mitochondria, and raising plasma levels does not reliably raise levels in heart, muscle or brain mitochondria.¹,² 

CoQ10 Repletion vs Mitochondrial Targeting 

The two molecules take different routes to the same membrane: CoQ10 supplementation is a repletion strategy, providing enough substrate that some reaches tissues and tops up the endogenous stores – it is most compelling when stores are low.²,³ 

Mitoquinol is a targeted strategy. It keeps the redox-active quinone head but replaces the long isoprenoid tail with a ten-carbon chain linked to triphenylphosphonium (TPP⁺), a lipophilic cation. That cation lets it cross membranes easily and accumulate according to membrane potential, so it concentrates in mitochondria rather than distributing passively.⁴,¹⁷ 

For CoQ10, success means a restored electron carrier pool: electron flow from complexes I and II to complex III recovers and ATP output follows. For mitoquinol, success means lower mitochondrial oxidative stress at the inner membrane, with less lipid peroxidation and DNA damage, while normal ROS signalling is preserved.⁵,¹⁰

How MitoQ and CoQ10 Work: Absorption, Uptake and Redox Cycling 

CoQ10 is absorbed like a dietary fat. It must be solubilised into bile-salt micelles, taken up by enterocytes, packaged into chylomicrons and delivered to the lymph.¹ Each stage is inefficient for a molecule this large and insoluble. Absorption is improved by taking CoQ10 with a fat-containing meal and by formulations that disperse its crystals; poorly dispersed crystalline CoQ10 can lose roughly three-quarters of its bioavailability.¹ Because uptake is saturable, divided doses usually outperform a single large dose.¹ The reduced form, ubiquinol, is often marketed as better absorbed, but the two forms interconvert in the gut and circulation, and comparative studies are mixed and heavily formulation-dependent.¹ 

Mitoquinol is a smaller amphiphilic cation that crosses membranes more readily, and plasma concentrations peak within about an hour of an oral dose.¹⁹ In mice, oral mitoquinol produced substantially higher mitochondrial levels than CoQ10 at a tenth of the dose.⁷ However, that comparison has not been replicated in human tissue. 

How MitoQ Enters Mitochondria: TPP⁺ and Membrane Potential 

The TPP⁺ cation is the defining feature of mitoquinol. Its positive charge is spread over three phenyl rings, so the molecule passes through lipid bilayers without a transporter.¹⁷ Uptake follows the Nernst relationship: roughly a tenfold accumulation for every 60 mV of membrane potential. The plasma membrane potential (about 30–60 mV, negative inside) concentrates it modestly in the cytosol. The far larger mitochondrial potential (about 150–180 mV) concentrates it several hundred-fold in the mitochondrial matrix.⁴,¹⁷ The molecule then adsorbs to the matrix face of the inner membrane, with its quinone head inserted into the lipid core.⁶ 

Because uptake depends on membrane potential, mitoquinol accumulates most where mitochondria are numerous and actively producing energy, such as the heart, skeletal muscle, liver, kidney and brain.¹⁸ Conversely, severely damaged mitochondria with substantially reduced membrane potential are likely to accumulate less mitoquinol. 

Does MitoQ Replace CoQ10 in the Electron Transport Chain? 

No - CoQ10 keeps the energy-producing chain running, and mitoquinol protects the membrane that chain sits in. CoQ10 is an electron carrier, and it picks up electrons at complexes I and II and drops them off at complex III inside the electron transport chain. That pick-up and drop-off cycle is what keeps the chain moving and ATP being made. 

Mitoquinol can only do half of that job. Complex II loads it with electrons efficiently. However, its bulky TPP⁺ group sits near the membrane surface and holds the quinone head out of reach of complexes I and III, so it unloads electrons there only very slowly.⁵,⁶ Because it can’t pass electrons along the chain, mitoquinol can’t restore energy production in mitochondria that are short of CoQ10.⁵ 

What it does instead is act as a recyclable antioxidant. In its active (ubiquinol) form, it gives up a hydrogen atom to neutralise lipid radicals. This stops the chain reaction of lipid peroxidation that would otherwise damage mitochondrial membranes. Complex II then reloads the spent molecule and returns it to its active form, ready to neutralise another radical. This recycling is why a small dose can go a long way.⁵,¹⁷ 

MitoQ Safety, Dose and Pro-oxidant Potential 

Like other quinones, mitoquinol is not purely an antioxidant. At very high concentrations, well above anything reached with oral supplements, laboratory studies show it can generate free radicals (superoxide) rather than neutralise them. Its TPP⁺ group can also slightly weaken the mitochondrial membrane’s charge.⁵ These findings come from isolated mitochondria, not people, but they are a reminder that more is not always better and that results from cell studies don’t translate directly to supplement doses. At intended intakes, mitoquinol mesylate has shown no genetic toxicity in laboratory tests, and a 39-week oral toxicity study in animals found it safe.¹⁵ 

MitoQ vs CoQ10 in a Head-to-Head Human Trial 

The clearest direct comparison comes from a New Zealand trial in healthy, middle-aged, untrained men.⁸ Participants took 20 mg/day of mitoquinol, 200 mg/day of CoQ10 or placebo for six weeks. Researchers then took muscle biopsies and measured mitochondrial hydrogen peroxide (H₂O₂), respiration and systemic oxidative stress markers. 

Both supplements lowered net mitochondrial H₂O₂ during leak respiration, the state in which ROS output is typically highest. Only mitoquinol also increased muscle catalase, an enzyme that breaks down H₂O₂ and is part of the cell’s own antioxidant defence. Mitoquinol produced these effects at one-tenth of the CoQ10 dose. However, neither supplement changed mitochondrial respiration, urinary F₂-isoprostanes or plasma TBARS.⁸ 

That pattern demonstrates that in people with no deficiency and normal mitochondrial function, neither molecule is expected to raise ATP capacity. What changes is the redox environment around the mitochondria and later trials in similar populations built on this: 

In untrained men, 20 mg/day of mitoquinol during training augmented exercise-induced PGC-1α signalling and improved gains in peak power, without changing mitochondrial content.⁹ In trained cyclists, it improved 8 km time-trial performance.¹⁶ After high-intensity exercise, it reduced mitochondrial and nuclear DNA damage in lymphocytes.¹⁰ 

This example also highlights that exercise-induced ROS are partly the signal for adaptation. Broad, high-dose antioxidants can blunt that signal, which is why targeting and modest dosing matter more than maximal suppression. 

CoQ10 Deficiency vs Mitochondrial Oxidative Stress 

Two different failures can sit behind mitochondrial dysfunction:  

  1. Carrier depletion: primary CoQ10 deficiencies are rare genetic disorders of CoQ10 synthesis. Secondary depletion is more common and can arise with ageing, statin therapy (statins inhibit HMG-CoA reductase, upstream of both cholesterol and CoQ10 synthesis) and some chronic diseases.² Here, electron transfer itself is limited, and replacing CoQ10 is the logical response. 

  1. Oxidative overload with an intact carrier pool: electron flow continues, but ROS production outpaces local defenses. Lipid peroxidation damages cardiolipin and membrane integrity, oxidised mitochondrial DNA accumulates, and redox-sensitive signalling shifts toward inflammation and endothelial dysfunction.¹⁷ Adding more CoQ10 to stores that are already adequate does little to change the redox balance at the inner membrane. A targeted antioxidant like mitoquinol is better matched to this problem. 

In practice these states overlap, especially in older adults. A person on long-term statin therapy may have both reduced CoQ10 and elevated vascular oxidative stress. 

Conditions Linked to CoQ10 Depletion and Mitochondrial ROS 

Dysregulated processConditions investigatedWhy they may be connected
CoQ10 depletionPrimary CoQ10 deficiencies; statin-associated muscle symptoms; chronic heart failureReduced carrier limits electron transfer. Strongest CoQ10 outcome evidence is in heart failure; statin myopathy trials are mixed2,3
Mitochondrial ROS and endothelial dysfunctionAge-related vascular stiffness; hypertension; peripheral artery diseaseMitochondrial ROS reduce nitric oxide availability. Mitoquinol improved endothelial function in older adults; trials are small and short11,13
Oxidative damage to kidney and liverChronic kidney disease; hepatitis CHigh-energy organs accumulate mitoquinol. Pilot and phase II data show vascular and ALT changes, not hard outcomes12,14
Exercise-related oxidative stressTraining load; sarcopenia-prone ageingMitoquinol reduced DNA damage and improved power in small trials; clinical relevance in frail populations is untested9,10

 Choosing Between MitoQ and CoQ10 in Clinic 

FeatureCoQ10 (ubiquinone/ubiquinol)Mitoquinol (MitoQ)
StructureQuinone head with a 50-carbon isoprenoid tailQuinone head with a 10-carbon chain linked to TPP+
Typical studied dose100–300 mg/day, often divided1,310–20 mg/day (up to 40–80 mg in some trials)8,13,14
AbsorptionLow, saturable, fat- and formulation-dependent1Rapid; plasma peak around one hour19
Route into mitochondriaNo dedicated transporter; slow tissue uptake1Driven by membrane potential; several hundred-fold matrix accumulation4
Role in the ETCElectron carrier between complexes I/II and IIIReduced by complex II, poorly oxidised by complex III; not a substitute5,6
Primary actionRepletes electron carrier pool; membrane antioxidantRecyclable antioxidant at the inner membrane
Strongest human evidenceChronic heart failure outcomes3Vascular function, exercise and oxidative-damage markers9,10,11

Lifestyle and Medication Factors that Affect CoQ10 and Mitochondrial Redox 

FactorPotential roleEvidence and cautions
Regular aerobic and resistance exerciseExpands mitochondrial content and endogenous antioxidant capacityStrongest human evidence of any intervention here; should come first
Dietary fat with CoQ10Improves micellar absorption of CoQ10Practical and low-cost; formulation matters as much as timing1
Statin therapyLowers CoQ10 synthesisSupplementing is reasonable; evidence for symptom relief is inconsistent2
Ageing, smoking, metabolic diseaseRaise mitochondrial ROS and lower antioxidant reserveContext for targeted antioxidant use, not an indication on its own
High-dose untargeted antioxidants around trainingMay blunt exercise adaptationSeparate timing from training or favour targeted, modest dosing

Can MitoQ and CoQ10 be Taken Together? 

CoQ10 is the first choice when the aim is repletion: a known or likely deficiency, statin use, or heart failure, where outcome data exist.³ Mitoquinol is the better-matched tool when CoQ10 stores are likely adequate, and the problem is oxidative stress at the mitochondrion - particularly in vascular ageing, high training loads or conditions with documented mitochondrial ROS. The two are complementary because mitoquinol does not replace CoQ10 in the ETC, and using both is mechanistically coherent where depletion and oxidative stress coexist.  

Most trials use 20 mg/day of mitoquinol. A practical approach for general cellular health is to start at 10 mg/day and assess response over two to three months.¹⁹ Clinical experience suggests people with chronic fatigue or primary mitochondrial disorders may prefer 5–10 mg/day, as some anecdotal evidence suggests that some find higher doses overly activating.¹⁹ 

MitoQ vs CoQ10 Research: Current Evidence 

CoQ10 is essential for electron transport, and oral absorption is limited and formulation-dependent.¹ In chronic heart failure, 300 mg/day for two years reduced major adverse cardiovascular events in the Q-SYMBIO trial.³  

Mitoquinol accumulates in mitochondria in proportion to membrane potential and acts as a recyclable antioxidant, but it cannot replace CoQ10 as an electron carrier.⁴,⁵,⁶ 

Human mitoquinol trials consistently show changes in oxidative stress markers, endothelial function and exercise performance, typically at 20 mg/day over three to twelve weeks.⁸,⁹,¹⁰,¹¹ Questions remain about which populations respond most, how long effects last after stopping, and whether vascular improvements translate into fewer cardiovascular events. 

Only one trial has compared the two molecules directly, and it found similar suppression of mitochondrial H₂O₂, with a catalase advantage for mitoquinol at a tenth of the dose.⁸ The mitochondrial bioavailability advantage comes from mouse data.⁷ No trial yet compares them on clinical outcomes, and long-term human safety data for mitoquinol are shorter than for CoQ10. 

Where Mitoquinol fits in Mitochondrial Research 

Mitoquinol was developed by Professor Mike Murphy and Dr Robin Smith specifically to solve CoQ10’s delivery problem. Its value lies in placing a recyclable antioxidant on the inner mitochondrial membrane at low oral doses, where untargeted antioxidants struggle to reach meaningful concentrations.⁴,¹⁷ 

More than 25 human trials have tested mitoquinol, most at 20 mg/day for three to twelve weeks. The strongest and most consistent findings are in vascular function, exercise-related oxidative damage and training response. The only head-to-head trial with CoQ10 found that 20 mg/day of mitoquinol matched 200 mg/day of CoQ10 in lowering muscle mitochondrial H₂O₂, and additionally increased catalase.⁸ 

AreaPopulationDose and durationMain findings
Head-to-head with CoQ10Healthy middle-aged men20 mg/day vs CoQ10 200 mg/day, 6 weeksBoth lowered muscle mitochondrial H2O2; only mitoquinol raised catalase. Neither changed respiration or systemic oxidative markers8
Vascular ageingHealthy older adults with impaired endothelial function (n = 20)20 mg/day, 6 weeksFlow-mediated dilation +42%; lower aortic stiffness and oxidised LDL11
HypertensionHypertensive men, with or without endurance training (n = 52)20 mg/day, 6 weeksLower systolic blood pressure, MDA and IL-620
Peripheral artery diseasePatients with PAD (n = 11)Single 80 mg doseImproved endothelial function and antioxidant enzyme activity; walking time +74 s13
Heart failureHeart failure with preserved ejection fraction20 mg/day, 4 weeksImproved immune-cell mitochondrial bioenergetics (conference abstract)23
KidneyChronic kidney disease, randomised pilot20 mg/dayImprovements in vascular function measures12
LiverChronic hepatitis C (n = 30)40 or 80 mg/day, 4 weeksLower serum ALT, a marker of liver injury14
Oxidative DNA damageHealthy men, high-intensity exercise20 mg/day, 3 weeksUp to 25% less exercise-induced mitochondrial and nuclear DNA damage10
Antioxidant capacityCyclists during vigorous training20 mg/day, 6 weeksROS reduced by up to 48%; higher glutathione peroxidase activity24
Training responseUntrained middle-aged men, high-intensity training20 mg/dayGreater PGC-1α response and larger gains in peak power, without change in mitochondrial content9
Endurance performanceTrained middle-aged cyclists (n = 19)20 mg/day, 4 weeks, crossover8 km time-trial power +4.4% vs placebo16
Muscle power with ageLate middle-aged and older adults20 mg/day, 6 weeksLeg extension power +11% (conference abstract)26
Muscle damage recoveryUntrained men after eccentric exercise (n = 32)20 mg/day, 14 days before exerciseNo effect on soreness or force recovery; recovery of eccentric torque was delayed22
Fatigue syndromesFibromyalgia and ME/CFS, open-label20 mg/day, 12 weeksReported less pain and better energy, sleep and cognition (not peer reviewed)25
NeurodegenerationParkinson's disease (n = 128)40–80 mg/day, 12 monthsNo effect on disease progression21

Read together, these studies show consistent target engagement: lower mitochondrial oxidative stress and less oxidative damage in vascular and muscle tissue. Functional benefits are clearest for endothelial function and training response. Trials are small and short, several are abstracts or open-label, and null results in Parkinson’s disease and muscle-damage recovery show that mitochondrial oxidative stress is not the limiting factor in every condition. 

FAQs 

Is MitoQ better than CoQ10? 

Both antioxidants perform differently. CoQ10 replaces an electron carrier that can run low with age, statins or deficiency. MitoQ (mitoquinol) concentrates an antioxidant inside mitochondria. In the only head-to-head trial, 20 mg of MitoQ matched 200 mg of CoQ10 in lowering muscle mitochondrial H₂O₂, and also raised catalase.⁸ 

What is the Difference between MitoQ and Ubiquinol? 

Ubiquinol is simply the reduced form of CoQ10. It shares CoQ10’s long isoprenoid tail and its absorption limits. MitoQ swaps that tail for a shorter chain linked to a positively charged TPP⁺ group, which drives it into mitochondria using membrane potential.¹,⁴ 

Can you take MitoQ and CoQ10 Together? 

Yes, the combination is mechanistically coherent. MitoQ does not replace CoQ10 in the electron transport chain, so the two do not compete for the same role.⁵ Combining them makes most sense where CoQ10 depletion and mitochondrial oxidative stress coexist, such as in older adults on statins. 

How Does the MitoQ Dose Compare to CoQ10? 

There is no direct dose equivalence, because the molecules act differently. Most MitoQ trials use 20 mg/day, compared with 100–300 mg/day for CoQ10.³,⁸ A common starting point for general cellular health is 10 mg/day of MitoQ.¹⁹ 

Should People Taking Statins Use CoQ10 or MitoQ? 

Statins lower CoQ10 synthesis, so CoQ10 is the logical first choice for repletion, although trials on statin muscle symptoms are mixed.² MitoQ can be added where vascular or mitochondrial oxidative stress is also a concern. 

Key takeaways 

  • CoQ10 and mitoquinol share a quinone head but serve different roles: CoQ10 is an electron carrier to replete, mitoquinol a targeted antioxidant. 

  • CoQ10’s main limitation is delivery: low, saturable absorption and no dedicated route into mitochondria. 

  • Mitoquinol uses membrane potential to concentrate several hundred-fold in mitochondria, but it cannot substitute for CoQ10 in the ETC. 

  • Use CoQ10 for depletion (statins, heart failure, deficiency) and mitoquinol for mitochondrial oxidative stress; the two can be combined. 

  • Direct human comparison rests on one six-week biomarker trial, so claims of superiority should stay proportionate. 

References 

  1. Mantle D, Dybring A. Bioavailability of coenzyme Q10: an overview of the absorption process and subsequent metabolism. Antioxidants. 2020;9(5):386. doi:10.3390/antiox9050386 

  2. Mantle D, Lopez-Lluch G, Hargreaves IP. Coenzyme Q10 metabolism: a review of unresolved issues. Int J Mol Sci. 2023;24(3):2585. doi:10.3390/ijms24032585 

  3. Mortensen SA, Rosenfeldt F, Kumar A, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO. JACC Heart Fail. 2014;2(6):641–649. doi:10.1016/j.jchf.2014.06.008 

  4. Kelso GF, Porteous CM, Coulter CV, et al. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem. 2001;276(7):4588–4596. doi:10.1074/jbc.M009093200 

  5. James AM, Cochémé HM, Smith RAJ, Murphy MP. Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species. J Biol Chem. 2005;280(22):21295–21312. doi:10.1074/jbc.M501527200 

  6. James AM, Sharpley MS, Manas AR, et al. Interaction of the mitochondria-targeted antioxidant MitoQ with phospholipid bilayers and ubiquinone oxidoreductases. J Biol Chem. 2007;282(20):14708–14718. doi:10.1074/jbc.M611463200 

  7. Woodhead B, Jaiswal J. Mitochondrial bioavailability of mitoquinol mesylate orally administered to mice. Biochim Biophys Acta Bioenerg. 2024;1865(Suppl):149344. EBEC 2024 abstract book, 22nd European Bioenergetics Conference (conference abstract).

  8. Pham T, MacRae CL, Broome SC, et al. MitoQ and CoQ10 supplementation mildly suppresses skeletal muscle mitochondrial hydrogen peroxide levels without impacting mitochondrial function in middle-aged men. Eur J Appl Physiol. 2020;120(7):1657–1669. doi:10.1007/s00421-020-04396-4 

  9. Broome SC, Pham T, Braakhuis AJ, et al. MitoQ supplementation augments acute exercise-induced increases in muscle PGC1α mRNA and improves training-induced increases in peak power independent of mitochondrial content and function in untrained middle-aged men. Redox Biol. 2022;53:102341. doi:10.1016/j.redox.2022.102341 

  10. Williamson J, Hughes CM, Cobley JN, Davison GW. The mitochondria-targeted antioxidant MitoQ attenuates exercise-induced mitochondrial DNA damage. Redox Biol. 2020;36:101673. doi:10.1016/j.redox.2020.101673 

  11. Rossman MJ, Santos-Parker JR, Steward CAC, et al. Chronic supplementation with a mitochondrial antioxidant (MitoQ) improves vascular function in healthy older adults. Hypertension. 2018;71(6):1056–1063. doi:10.1161/HYPERTENSIONAHA.117.10787 

  12. Kirkman DL, Stock JM, Shenouda N, et al. Effects of a mitochondrial-targeted ubiquinol on vascular function and exercise capacity in chronic kidney disease: a randomized controlled pilot study. Am J Physiol Renal Physiol. 2023;325(4):F448–F456. doi:10.1152/ajprenal.00067.2023 

  13. Park SY, Pekas EJ, Headid RJ, et al. Acute mitochondrial antioxidant intake improves endothelial function, antioxidant enzyme activity, and exercise tolerance in patients with peripheral artery disease. Am J Physiol Heart Circ Physiol. 2020;319(2):H456–H467. doi:10.1152/ajpheart.00235.2020.  

  14. Gane EJ, Weilert F, Orr DW, et al. The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int. 2010;30(7):1019–1026. doi.org/10.1111/j.1478-3231.2010.02250.x

  15. Mitchell ES, Lemke S, Woodhead B, Coleman D. Oral subchronic toxicity study and genetic toxicity evaluation of mitoquinone mesylate. J Appl Toxicol. 2024;44(10):1555–1571. 

  16. Broome SC, Braakhuis AJ, Mitchell CJ, Merry TL. Mitochondria-targeted antioxidant supplementation improves 8 km time trial performance in middle-aged trained male cyclists. J Int Soc Sports Nutr. 2021;18:58. doi:10.1186/s12970-021-00454-0 

  17. Murphy MP, Smith RAJ. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol. 2007;47:629–656. doi:10.1146/annurev.pharmtox.47.120505.105110 

  18. Smith RAJ, Murphy MP. Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann N Y Acad Sci. 2010;1201:96–103. doi:10.1111/j.1749-6632.2010.05627.x 

  19. MitoQ. Mitoquinol vs. CoQ10: practitioner guide (healthcare professional document; pharmacokinetic and dosing guidance).